Cryptolepine provokes changes in the expression of cell cycle proteins in growing cells

American Journal of Pharmacology and Toxicology

Volumn 4, Issue 4, 2009, Pages 177-185

  Ansah, Charles ^a   Gooderham, Nigel J ^b  

^a KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cell cycle arrest; Cryptolepine; P53

Indexed keywords

CELL CYCLE PROTEIN; CRYPTOLEPINE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL LINE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MAMMAL CELL;

MAMMALIA;

EID: 75349106609     PISSN: 15574962     EISSN: 15574970     Source Type: Journal    
DOI: 10.3844/ajptsp.2009.177.185     Document Type: Article

References (40)

1. Dwuma-Badu, D., J.S.K. Ayim, N.I.Y. Fiagbe, J.E. Knapp, P.L. Schiff Jr. and D.J. Slatkin, 1978. Constituents of West African medicinal plants XX: Quindoline from Cryptolepis sanguinolenta. J. Pharm. Sci., 67: 433-434. DOI: 10.1002/JPS.2600670350
2. Tachie, A.N., M.H.M. Sharaf, P.L. Schiff, G.L. Boye, R.C. Crouch and G.E. Martin, 1991. Assignment of the proton and carbon NMR spectra of the indoloquinoline alkaloid cryptolepine. J. Heterocyclic Chem., 28: 1429-1435. DOI: 10.1002/jhet.5570280540
3. Bonjean, K., M.C. De Pauw-Gillet, M.P. Defresne, P. Colson, C. Houssier, L. Dassonneville and L. Angenot et al., 1998. The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry, 37: 5136-5146. DOI: 10.1021/BI972927Q
4. Ansah, C. and N.J. Gooderham, 2002. The popular herbal antimalarial, extract of Cryptolepis sanguinolenta, is potently cytotoxic. Toxicol. Sci., 70: 245-251. DOI: 10.1093/TOXSCI/70.2.245
5. Dassonneville, L., A. Lansiaux, A. Wattelet, N. Wattez, C. Mahieu and C. Bailly et al., 2000. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Eur. J. Pharmacol., 409: 9-18. DOI: 10.1016/S0014-2999(00)00805-0
6. Lisgarten, J.N., M. Coll, J. Portugal, C.W. Wright and J. Aymami, 2002. The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat. Struct. Biol., 9: 57-60. DOI: 10.1038/NSB729
7. Ansah, C. and N.J. Gooderham, 2005. Reactive oxygen species is associated with cryptolepine cytotoxicity. J. Sci. Technol., 25: 1-10 http://ajol.info/ index.php/just/article/view/32926
8. Ansah, C., H. Zhu and N.J. Gooderham, 2008. The mechanism of cryptolepine-induced cell death. J. Pharmacol. Toxicol., 3: 291-301. DOI: 10.3923/JPT.2008.291.301
9. Livingstone, L.R., A. White, J. Sprouse, E. Livanos, T. Jacks and T.D. Tlsty, 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935. DOI: 10.1016/0092-8674(92) 90243-6
10. Volgestein, B., D. Lane and A.J. Levine, 2000. Surfing the p53 network. Nature, 408: 307-310. DOI: 10.1038/35042675
11. Chaung, W., L.J. Mi and R. Boorstein, 1997. The p53 status of Chinese hamster V79 cells frequently used for studies on DNA damage and DNA repair. Nucleic Acid Res., 25: 992-994. DOI: 10.1093/NAR/25.5.992
12. Morris, S.M., M.G. Manjanatha, S.D. Shelton, O.E. Domon, L.J. McGarrity and D.A. Casciano, 1996. A mutation in the p53 tumor suppressor gene of AHH-1 tk+/- human lymphoblastoid cells. Mutat. Res., 356: 129-134. DOI: 10.1016/0027-5107(96)00133-9
13. Kim, J.M., Y.D. Yoon and B.K. Tsang, 1999. Involvement of the Fas ligand in p53-mediated granulosa cell apoptosis during follicular development and atresia. Endocrinology, 140: 2307-2317. DOI: 10.1210/EN.140.5.2307
14. Crespi, C.L., F.J. Gonzalez, D.T. Steimel, T.R. Turner, H.V. Gelboin, B.W. Penman and R.A. Langenbach, 1991. Metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: Application to mutagenicity testing. Chem. Res. Toxicol., 4: 566-72. DOI: 10.1021/TX00023A013
15. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons and B. Vogelstein et al., 1993. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-25. DOI: 10.1016/0092-8674(93)90500-P
16. Barak, Y., T. Juven, R. Haffner and M. Oren, 1993. Mdm2 expression is induced by wild-type p53 activity. EMBO. J., 12: 461-468. http://www.ncbi.nlm. nih.gov/pubmed/8440237
17. Noamesi, B.K., A. Paine, G.C. Kirby, D.C. Warhurst and G.D. Philipson, 1991. In vitro anti-malarial action of cryptolepine, an indoquinoline. Trans. R. Soc. Trop. Med. Hyg., 85: 315.
18. Kirby, G.C., A. Paine, D.C. Warhurst, B.K. Noamesi and. J.D. Philipson, 1995. In vitro and in vivo anti-malarial activity of cryptolepine, a plant derived indoquinoline. Phytother. Res., 9: 359-363. DOI: 10.1002/PTR.2650090510
19. Wright, C.W., J.D. Philipson, S.O. Awe, G.C. Kirby, D.C. Warhurst et al., 1996. Antimalarial action of cryptolepine and some other anhydronium bases. Phytother. Res., 10: 361-363. DOI: 10.1002/(SICI)10991573(199606)10: 4<361::AID-PTR845> 3.0.CO;2-N
20. Dassonneville, L., K. Bonjean, M.C. De Pauw-Gillet, P. Colson, C. Houssier and C. Bailly et al., 1999. Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: Cryptolepine, matadine and serpentine. Biochemistry, 38: 7719-26. DOI: 10.1021/BI990094T
21. Clifford, B., M. Beljin, G.R. Stark and W.R. Taylor, 2003. G2 arrest in response to topoisomerase II inhibitors: The role of p53. Cancer Res., 63: 4074-81. http://www.ncbi.nlm.nih.gov/pubmed/12874009
22. Chow, K.C. and W.E. Ross, 1987. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol. Cell Biol., 7: 3119-3123. http://www.ncbi.nlm.nih.gov/pubmed/2823120
23. Ross, D., W. Thomas and C. Holm, 1990. Degradation of recombined chromosomes in meiosis I requires topoisomerase II. Cell, 60: 1009-1017. DOI: 10.1016/0092-8674(90)90349-J
24. Lane, D.P., 1992. p53: guardian of genome. Nature, 358: 15-16. DOI: 10.1038/358015a0
25. Hartwell, L.H. and T.A. Weinert, 1989. Checkpoints: Controls that ensure the order of cell cycle events. Science, 246: 629-34. DOI: 10.1126/SCIENCE. 2683079
26. Gottlieb, T.M. and M. Oren, 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287: 77-102. DOI: 10.1016/0304-419x(95)00019-C
27. Ko, L.J. and C. Prives, 1996. p53: Puzzle and paradigm. Genes Dev., 10: 1054-72. DOI: 10.1101/GAD.10.9.1054
28. Levine, A.J., 1997. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-31. DOI: 10.1016/S0092-8674(00)81871-1
29. Miyashita, T., S. Krajewski, M. Krajewska, H.G. Wang and H.K. Lin et al., 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-805. http://www.ncbi.nlm.nih.gov/pubmed/8183579
30. Juven, T., Y. Barak, A. Zauberman, D.L. George and M. Oren, 1993. Wild-type p53 can mediate sequence specific transactivation of an internal promoter within the MDM2 gene. Oncogene, 8: 3411-3416. http://www.ncbi.nlm.nih. gov/pubmed/8247544
31. Sherr, C. and J.M. Roberts, 1999. CDK inhibitors: positive and negative regulators of G1 phase progression. Genes Dev., 13: 1501-1512. DOI: 10.1101/GAD.13.12.1501
32. Roberts, J.M., 1999. Evolving ideas about cyclins. Cell, 98: 129-132. http://www.cell.com/biophysj/abstract/S0962-8924(97)01114-8
33. Sandal, T., 2002. Molecular aspects of the mammalian cell cycle and cancer. Oncologists, 7: 73-81. http://theoncologist.alphamedpress.org/cgi/ content/abstract/7/1/73
34. Chen, P.L., P. Scully, J.Y. Shew, J.Y. Wang and W.H. Lee, 1989. Phosphorylation of the RB gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198. http://www.cell.com/comments/ 0092-8674(89)90517-5
35. Riley, D.L., E.Y. Lee and W.H. Lee, 1994. The pRB: More than a tumor suppressor. Ann. Rev. Cell Biol., 10: 1-29. DOI: 10.1146/ANNUREV.CB.10.110194. 000245
36. Weinberg, R.A., 1995. The molecular basis of oncogenes and tumor suppressor genes. Ann. N. Y. Acad. Sci., 758: 331-338. DOI: 10.1111/j.1749-6632. 1995.tb24838.x
37. Hartwell, L.H. and M.B. Kastan, 1994. Cell cycle control and cancer. Science, 266: 1821-1828. DOI: 10.1126/SCIENCE.7997877
38. Harrington, E.A., J.L. Bruce, E. Harlow and N. Dyson, 1998. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl. Acad. Sci. USA., 95: 11945-50. http://ukpmc.ac.uk/articlerender.cgi?artid=270037
39. Wang, Q., G. P. Zambetti and D.P. Suttle, 1997. Inhibition of DNA Topoisomerase IIα gene expression by the p53 tumor suppressor. Mol. Cell Biol., 17: 389-397. http://www.pubmedcentral.nih.gov/picrender.fcgi? artid=231763&blobtype=pdf
40. Soussi, T., 2000. The p53 tumor suppressor gene: From molecular biology to clinical investigation. Ann. N. Y. Acad. Sci., 910: 121-139. http://www.ncbi.nlm.nih.gov/pubmed/10911910